8-K: Blade Air Mobility Sells Passenger Unit, Rebrands

Blade Air Mobility announced the sale of its Passenger division to Joby Aviation for up to $125 million, with the remaining Medical division to rebrand as Strata Critical Medical, Inc., alongside strong Q2 2025 financial performance.

Summary

• Blade Air Mobility announced the sale of its Passenger division to Joby Aviation for up to $125 million.
• Blade's Medical division will remain a standalone public company and will rebrand as Strata Critical Medical, Inc.
• Net loss improved by $7.6 million year-over-year to $(3.7) million in Q2 2025.
• Adjusted EBITDA improved by $2.2 million year-over-year to $3.2 million in Q2 2025.
• Medical revenue increased 17.6% year-over-year to $45.1 million in Q2 2025.
• Total revenue increased 4.2% to $70.8 million in Q2 2025; excluding Canada (operations exited August 2024), revenue increased 8.5%.
• Passenger Flight Margin increased to 30.5% from 24.7% in the prior year period.
• Medical Flight Margin decreased to 22.0% from 23.6% in the prior year period.
• The company ended Q2 2025 with $113.4 million in cash and short-term investments.
• Full-year 2025 guidance (pre-divestiture) was reaffirmed: Revenue of $245-265 million and double-digit Adjusted EBITDA.

Sentiment

Score: 8

Explanation: The strategic divestiture of the passenger business, while a significant change, is presented as a positive, value-creating move that allows the company to focus on its high-growth, stable medical transport segment. The financial results for Q2 2025 show strong improvements in profitability metrics (net loss, Adjusted EBITDA) and continued growth in the core medical business. The pro forma cash position of $200 million for Strata is also a strong positive. While there are some revenue declines in the passenger segment, the overall narrative and financial performance indicate a strong strategic repositioning.

Positives

• Net loss improved significantly by $7.6 million year-over-year to $(3.7) million in Q2 2025.
• Adjusted EBITDA increased by $2.2 million year-over-year to $3.2 million in Q2 2025, representing a 233% increase.
• Medical revenue grew 17.6% year-over-year to $45.1 million in Q2 2025, driving overall revenue growth.
• Total revenue increased 4.2% to $70.8 million in Q2 2025, and 8.5% excluding the impact of Canada operations.
• Passenger Adjusted EBITDA improved by $1.6 million to $2.4 million in Q2 2025.
• Medical Adjusted EBITDA increased $0.5 million to $6.0 million in Q2 2025.
• Passenger Flight Margin improved to 30.5% from 24.7% in Q2 2024, driven by restructuring in Europe and the exit from Canada.
• The divestiture is expected to be Adjusted EBITDA and Free Cash Flow neutral on a go-forward annualized basis, supported by approximately $7 million in estimated corporate cost efficiencies.
• Strata (Medical division) will have approximately $200 million of cash and short-term investments on the balance sheet pro forma for the upfront portion of the Blade Passenger sale.
• A long-term partnership with Joby Aviation will provide future access to Joby eVTOLs for Strata's medical use, potentially offering lower operating costs and noise profiles.

Negatives

• Short Distance revenue decreased (17.8)% to $17.2 million in Q2 2025, primarily due to lower U.S. demand following a New York tourist helicopter incident in April 2025 and inclement weather.
• Jet and Other revenue decreased (2.3)% to $8.5 million in Q2 2025 due to a modest decline in flight volumes and revenue per flight.
• Medical Flight Margin decreased to 22.0% from 23.6% in Q2 2024 due to elevated maintenance downtime and maintenance costs.
• Operating Cash Flow was $(3.1) million in Q2 2025, driven primarily by an increase in working capital.
• Free Cash Flow, Before Aircraft Acquisitions, was $(5.7) million in Q2 2025.
• Seats flown for all passenger flights decreased to 22,730 in Q2 2025 from 27,391 in Q2 2024 (excluding Canada).

Risks

• The occurrence of any event, change, or circumstance that could give rise to the termination of the agreement to divest Blade's Passenger business or a delay in consummating the transactions.
• The effect of the announcement of the proposed transaction on Blade's business relationships, operating results, and business generally.
• Unexpected costs, charges, or expenses resulting from the proposed divestiture.
• Any failure to realize the anticipated efficiencies and benefits of such transaction.
• Fluctuations in the value of any equity issued to Blade in the transaction.
• Continued incurrence of significant losses.
• Failure of the markets for offerings to grow as expected, or at all.
• Ability to effectively market and sell air transportation as a substitute for conventional methods of transportation.
• Reliance on certain customers in the Passenger segment revenue.
• The inability or unavailability to use or take advantage of the shift, or lack thereof, to EVA technology.
• Ability to successfully enter new markets and launch new routes and services.
• Any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving third-party operators.
• The impact of the recently announced sale of the Passenger business, the ability to successfully complete such sale on a timely basis or at all, and any inability to realize the anticipated benefits of such transaction.
• Any change to the ownership of aircraft and the challenges related thereto.
• The effects of competition.
• Harm to reputation and brand.
• Ability to provide high-quality customer support.
• Ability to maintain a high daily aircraft usage rate.
• Changes in consumer preferences, discretionary spending and other economic conditions.
• Impact of natural disasters, outbreaks and pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions or other circumstances on metropolitan areas and airports where there is geographic concentration.
• The effects of climate change, including potential increased impacts of severe weather and regulatory activity.
• The availability of aircraft fuel.
• Ability to address system failures, defects, errors, or vulnerabilities in website, applications, backend systems or other technology systems or those of third-party technology providers.
• Interruptions or security breaches of information technology systems.
• Placements within mobile applications.
• Ability to protect intellectual property rights.
• Use of open source software.
• Ability to expand and maintain infrastructure network.
• Ability to access additional funding.
• The increase of costs and risks associated with international expansion.
• Ability to identify, complete and successfully integrate future acquisitions.
• Ability to manage growth.
• Increases in insurance costs or reductions in insurance coverage.
• The loss of key members of the management team.
• Ability to maintain company culture.
• Reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations.
• Effects of fluctuating financial results.
• Reliance on third-party operators.
• The availability of third-party operators.
• Disruptions to third-party operators.
• Increases in insurance costs or reductions in insurance coverage for third-party aircraft operators.
• The possibility that third-party aircraft operators may illegally, improperly or otherwise inappropriately operate branded aircraft.
• Reliance on third-party web service providers.
• Changes in the regulatory environment.
• Risks and impact of any litigation.
• Regulatory obstacles in local governments.
• The expansion of domestic and foreign privacy and security laws.
• The expansion of environmental regulations.
• Ability to remediate any material weaknesses or maintain internal controls over financial reporting.
• Ability to maintain effective internal controls and disclosure controls.
• Changes in the fair value of warrants.

Future Outlook

Blade Air Mobility reaffirmed its full-year 2025 revenue guidance of $245-265 million and double-digit Adjusted EBITDA on a full-company basis, excluding the impact of the divestiture. Updated guidance will be provided after the transaction closes. The divestiture of the Passenger division is expected to be Adjusted EBITDA and Free Cash Flow neutral on a go-forward annualized basis, supported by approximately $7 million in estimated corporate cost efficiencies.

Management Comments

• "This divestiture is transformational for both the Blade Passenger business and Blades Medical division, that will remain a standalone publicly traded company. We strongly believe that this is the best path forward to create long term value for all stakeholders including employees, customers, partners and shareholders." Rob Wiesenthal, Chief Executive Officer.
• "Blades Medical business has grown from 12% of revenue in 2020 to over 60% of revenue over the last year." Rob Wiesenthal, Chief Executive Officer.
• "I'm thrilled to announce that I will be joining Joby Aviation as CEO of Blade Air Mobility when the transaction closes. Blade's Medical division will remain a separate public company to be rebranded as Strata, where I will serve as Chairman of the Board." Rob Wiesenthal, Chief Executive Officer.
• "Post-close, Strata will be a pure-play, contractual healthcare solutions business with no direct reimbursement risk, limited economic sensitivity and an attractive multi-year growth profile." Melissa Tomkiel, President.
• "The long-term partnership announced with Joby Aviation as part of the transaction will provide future access to Joby eVTOLs for Strata's medical use. We expect that our use of Joby eVTOLs will provide value to Strata customers and a competitive advantage for the Company, given their lower noise profile and potential to operate at lower costs than traditional aircraft." Melissa Tomkiel, President.
• "Strata has a clear value creation strategy over the coming years driven by strong underlying organic growth and a highly focused and disciplined capital allocation strategy supported by approximately $200 million of cash and short-term investments on the balance sheet, pro forma for the up-front portion of the Blade Passenger sale." Will Heyburn, Chief Financial Officer.
• "Importantly, the financial impact of the divestiture is expected to be Adjusted EBITDA and Free Cash Flow neutral on a go forward annualized basis, supported by approximately $7 million in estimated corporate cost efficiencies. What's more, we're announcing this transformation from a position of strength that is reflected in our strong Q2 2025 financial performance, which has continued in Q3 to-date." Will Heyburn, Chief Financial Officer.

Industry Context

This announcement signifies a strategic pivot for Blade Air Mobility, moving away from the consumer passenger air mobility market to focus entirely on the high-growth, less economically sensitive medical logistics sector. The sale of the passenger division to Joby Aviation, a leading eVTOL developer, aligns with the broader industry trend towards specialized operations and the eventual integration of advanced air mobility (AAM) technologies like eVTOLs. By focusing on medical transport, rebranded as Strata Critical Medical, the company aims to capitalize on the stable demand for organ and critical medical supply transport, a niche with strong contractual revenue streams and limited reimbursement risk, differentiating itself from passenger-focused competitors like traditional charter services. The partnership with Joby for future eVTOL access positions Strata to potentially gain a competitive advantage through lower operating costs and noise profiles, aligning with the future of air transport.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The strategic shift to a 'pure-play, contractual healthcare solutions business with no direct reimbursement risk' positions Strata in a more stable and predictable segment compared to the more volatile consumer air mobility market.
• The long-term partnership with Joby Aviation for eVTOL access for medical use suggests an alignment with future industry trends towards advanced air mobility, potentially offering a competitive advantage in efficiency and cost over traditional aircraft used by other medical transport providers.

Management Changes

Corporate Governance

Legal Proceedings

• Legal and regulatory advocacy fees were incurred primarily related to the Drulias lawsuit.

Related Party Transactions

• No related party transactions were explicitly disclosed beyond the strategic sale of the Passenger division to Joby Aviation, which is a significant business transaction rather than a typical related party dealing in the context of ongoing operations.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through focus on the high-growth, stable medical segment; receipt of up to $125 million from the sale; potential for two separate public entities (BLDE ticker for Strata, Joby shares for Passenger business).
• Employees: Rob Wiesenthal transitioning to Joby Aviation as CEO of Blade Air Mobility (Passenger business), while Will Heyburn and Melissa Tomkiel become co-CEOs of Strata (Medical business), implying continuity for Medical division employees and integration for Passenger division employees into Joby.
• Customers (Medical): Continued service under Strata Critical Medical, Inc., with future access to Joby eVTOLs potentially offering lower costs and noise.
• Customers (Passenger): Service to be integrated into Joby Aviation.
• Partners: A long-term partnership established between Joby Aviation and Strata for eVTOL access.
• Creditors: Pro forma cash and short-term investments of approximately $200 million for Strata post-sale suggests a strong financial position.

Next Steps

• Closing of the Passenger divestiture to Joby Aviation.
• Rebranding of the Medical division as Strata Critical Medical, Inc.
• Announcement of a new ticker symbol for Strata at a later date.
• Updated financial guidance to be provided following the close of the transaction.
• A conference call was conducted on August 5, 2025, to discuss the results and divestiture.

Key Dates

Recommendation

The strategic divestiture of the Passenger division to Joby Aviation for up to $125 million, coupled with the rebranding and focus on the high-growth, stable Medical segment (Strata Critical Medical), represents a highly positive and transformative move. The Q2 2025 financial results demonstrate significant improvements in net loss and Adjusted EBITDA, driven by the Medical segment's strong performance. The pro forma cash position of $200 million for Strata provides substantial financial flexibility. This strategic shift de-risks the business by focusing on a contractual healthcare solutions model with limited economic sensitivity, while the partnership with Joby Aviation for eVTOL access positions the company for future competitive advantages. The expected Adjusted EBITDA and Free Cash Flow neutrality of the divestiture further underscores a well-executed strategic pivot, making the stock an attractive long-term investment.

Keywords

Air Mobility, Medical Transport, Organ Transport, eVTOL, Joby Aviation, Strata Critical Medical, SEC Filing, Financial Results, Divestiture, BLDE, Healthcare Logistics